Drug Target Insights最新文献_第4页

Are calcium channel blockers related to lung cancer? 钙通道阻滞剂与肺癌有关吗?

IF 2.7

Drug Target Insights Pub Date : 2023-01-01 DOI: 10.33393/dti.2023.2573

Ratchanon Rattanathanoo, Jarin Chindaprasirt, Watchara Boonsawat, Panita Limpawattana, Sittichai Khamsai, Kittisak Sawanyawisuth

{"title":"Are calcium channel blockers related to lung cancer?","authors":"Ratchanon Rattanathanoo, Jarin Chindaprasirt, Watchara Boonsawat, Panita Limpawattana, Sittichai Khamsai, Kittisak Sawanyawisuth","doi":"10.33393/dti.2023.2573","DOIUrl":"https://doi.org/10.33393/dti.2023.2573","url":null,"abstract":"Abstract Background: Calcium channel blocker (CCB) is a common antihypertensive agent for the treatment of hypertension. There are inconsistent data of an association of CCB and lung cancer in the literature. This study aimed to evaluate this association by a case-control design. Methods: The inclusion criteria were adult patients 18 years or over, diagnosed with hypertension, lung cancer or pulmonary tuberculosis, and presenting with one of the suggestive symptoms of lung cancer. Those who were pregnant or had a diagnosis of lung cancer or pulmonary tuberculosis prior to the diagnosis of hypertension were excluded. Diagnosis of lung cancer was made pathologically, while tuberculosis was made by positive acid-fast bacilli on sputum examination, sputum culture positive for Mycobacterium tuberculosis, or polymerase chain reaction positive for M. tuberculosis with a chest x-ray compatible with tuberculosis. Cases were those diagnosed with lung cancer, while controls were those diagnosed with tuberculosis. Factors associated with lung cancer were calculated by logistic regression analysis. Results: There were 178 patients who met the study criteria. Of those, 69 patients (38.8%) were in the case group. The lung cancer group had EGFR gene mutation in 21 patients (52.5%) and adenocarcinoma was the most common cell type of lung cancer (55 patients; 79.7%). There were two factors independently associated with lung cancer including dyslipidemia and family history of lung cancer. Conclusions: CCB was not associated with lung cancer in patients with hypertension but dyslipidemia and family history of lung cancer were independently associated with lung cancer in this setting.","PeriodicalId":11326,"journal":{"name":"Drug Target Insights","volume":"17 ","pages":"54-57"},"PeriodicalIF":2.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e4/b6/dti-17-54.PMC10203876.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9526478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Activity of sotorasib against brain metastases from NSCLC harboring KRAS p.G12C mutation: a case report. sotorasib对KRAS p.G12C突变的非小细胞肺癌脑转移的活性:1例报告。

IF 2.7

Drug Target Insights Pub Date : 2023-01-01 DOI: 10.33393/dti.2023.2593

Alessandro Inno, Fabiana Marchetti, Matteo Valerio, Niccolò Giaj Levra, Filippo Alongi, Giovanni Foti, Stefania Gori

引用次数: 1

Efficacy of LAMP assay for Mycobacterial spp. detection to prevent treatment delays and onset of drug resistance: a systematic review and meta-analysis. LAMP法检测分枝杆菌预防治疗延误和耐药的疗效:一项系统综述和荟萃分析。

IF 2.7

Drug Target Insights Pub Date : 2023-01-01 DOI: 10.33393/dti.2023.2596

Gurvinder Singh Bumbrah, Sarika Jain, Zeeshan Fatima, Saif Hameed

{"title":"Efficacy of LAMP assay for Mycobacterial spp. detection to prevent treatment delays and onset of drug resistance: a systematic review and meta-analysis.","authors":"Gurvinder Singh Bumbrah, Sarika Jain, Zeeshan Fatima, Saif Hameed","doi":"10.33393/dti.2023.2596","DOIUrl":"https://doi.org/10.33393/dti.2023.2596","url":null,"abstract":"Background: Tuberculosis (TB) remains a deadly disease affecting one-third population globally. Long turnaround time and poor sensitivity of the conventional diagnostics are the major impediments for faster diagnosis of Mycobacterial spp to prevent drug resistance. To overcome these issues, molecular diagnostics have been developed. They offer enhanced sensitivity but require sophisticated infrastructure, skilled manpower and remain expensive.Methods: In that context, loop-mediated isothermal amplification (LAMP) assay, recommended by the WHO in 2016 for TB diagnosis, sounds as a promising alternative that facilitates visual read outs. Therefore, the aim of the present study is to conduct a meta-analysis to assess the diagnostic efficiency of LAMP for the detection of a panel of Mycobacterium spp. following PRISMA guidelines using scientific databases. From 1600 studies reported on the diagnosis of Mycobacterium spp., a selection of 30 articles were identified as eligible to meet the criteria of LAMP based diagnosis.Results: It was found that most of the studies were conducted in high disease burden nations such as India, Thailand, and Japan with sputum as the most common specimen to be used for LAMP assay. Furthermore, IS6110 gene and fluorescence-based detections ranked as the most used target and method respectively. The accuracy and precision rates mostly varied between 79.2% to 99.3% and 73.9% to 100%, respectively. Lastly, a quality assessment based on QUADAS-2 of bias and applicability was conducted.Conclusion: LAMP technology could be considered as a feasible alternative to current diagnostics considering high burden for rapid testing in low resource regions.","PeriodicalId":11326,"journal":{"name":"Drug Target Insights","volume":"17 ","pages":"78-89"},"PeriodicalIF":2.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d4/e1/dti-17-78.PMC10249090.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9619511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lipid profiles of people with human immunodeficiency virus with dyslipidemia after switching from efavirenz to dolutegravir. 从依非韦伦切换到多替格拉韦后，伴有血脂异常的人类免疫缺陷病毒患者的脂质谱。

IF 2.7

Drug Target Insights Pub Date : 2023-01-01 DOI: 10.33393/dti.2023.2529

Supphachoke Khemla, Atibordee Meesing, Wantin Sribenjalux, Ploenchan Chetchotisakd

{"title":"Lipid profiles of people with human immunodeficiency virus with dyslipidemia after switching from efavirenz to dolutegravir.","authors":"Supphachoke Khemla, Atibordee Meesing, Wantin Sribenjalux, Ploenchan Chetchotisakd","doi":"10.33393/dti.2023.2529","DOIUrl":"https://doi.org/10.33393/dti.2023.2529","url":null,"abstract":"ABSTRACT Introduction: Human immunodeficiency virus (HIV) infection and the long-term use of antiretroviral therapy, especially efavirenz (EFV)-based regimens, impact lipid profiles due to insulin resistance and lead to a higher risk of metabolic diseases. Dolutegravir (DTG) is an integrase inhibitor with better lipid profiles than EFV. However, data on treatment experience in Thailand are limited. The primary outcome was lipid profile changes at 24 weeks after switching therapy. Methods: We conducted a prospective, open-label, cohort study in people with HIV aged ≥18 years who had undergone at least 6 months of EFV-based therapy, had HIV-1 ribonucleic acid levels <50 copies/mL for ≥6 months before switching, and were diagnosed with dyslipidemia or had risk factors for atherosclerosis cardiovascular disease based on modified National Cholesterol Education Program Adult Treatment Panel III guidelines. Results: Sixty-four patients were enrolled. The mean age (standard deviation [SD]) was 48.20 ± 10.46 years, and 67.19% were male. At week 24, there were decreases from baseline in mean total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides. However, mean body weight and waist circumference had increased. Conclusions: DTG resulted in better lipid profiles after switching from EFV-based therapy, suggesting that this switch could benefit patients with a high risk of cardiovascular disease. However, it is essential to note that weight gain and increased waist circumference were also observed.","PeriodicalId":11326,"journal":{"name":"Drug Target Insights","volume":"17 ","pages":"45-53"},"PeriodicalIF":2.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/85/b8/dti-17-45.PMC10158613.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9433065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Association between cardiovascular diseases and periodontal disease: more than what meets the eye. 心血管疾病和牙周病之间的联系:不仅仅是眼睛看到的。

IF 2.7

Drug Target Insights Pub Date : 2023-01-01 DOI: 10.33393/dti.2023.2510

Bhavya Shetty, Ibrahim Fazal, Safiya Fatima Khan, Manjusha Nambiar, Khadijathul Irfana D, Rohit Prasad, Akshata Raj

引用次数: 0

Natural Products & Phytotherapeutics: why a new section? 天然产品与植物疗法:为什么要设立一个新版块?

IF 2.7

Drug Target Insights Pub Date : 2023-01-01 DOI: 10.33393/dti.2023.2548

Marcello Iriti

引用次数: 0

Antimicrobial resistance surveillance system mapping in different countries. 不同国家的抗菌药耐药性监测系统分布图。

IF 2

Drug Target Insights Pub Date : 2022-11-30 eCollection Date: 2022-01-01 DOI: 10.33393/dti.2022.2482

Ramendra Pati Pandey, Riya Mukherjee, Chung-Ming Chang

引用次数: 0

Understanding the environmental drivers of clinical azole resistance in Aspergillus species. 了解曲霉菌临床抗唑的环境驱动因素。

IF 2.7

Drug Target Insights Pub Date : 2022-11-22 eCollection Date: 2022-01-01 DOI: 10.33393/dti.2022.2476

Pooja Sen, Mukund Vijay, Shweta Singh, Saif Hameed, Pooja Vijayaraghavan

{"title":"Understanding the environmental drivers of clinical azole resistance in Aspergillus species.","authors":"Pooja Sen, Mukund Vijay, Shweta Singh, Saif Hameed, Pooja Vijayaraghavan","doi":"10.33393/dti.2022.2476","DOIUrl":"https://doi.org/10.33393/dti.2022.2476","url":null,"abstract":"ABSTRACT Aspergilli are ubiquitous fungal pathogens associated with severe life-threatening infections, especially in immunocompromised patients. Azoles are the first line of defence in the fight against most Aspergillus-related infections. However, resistance to these therapeutic compounds has developed, which is mainly due to the existence of mutations in lanosterol 14 alpha-demethylase (Cyp51A), a crucial enzyme in the pathway that produces ergosterol and is the target of azole antifungals. Azole-based antifungal medications are ineffective because of infections brought on by azole-resistant Aspergillus species, leading to a high fatality rate. However, resistant Aspergillus isolates have also been isolated from azole-naïve patients. Global agricultural practices promote the use of azole fungicides to protect crops from phytopathogens. Usage of azole fungicides on a large scale has been linked to the development of resistance among Aspergillus species prevalent in the environment. The infections caused by these azole-resistant Aspergillus species cannot be treated by the available azole drugs, in turn leading to high morbidity and mortality rates. Thus, knowledge of the environmental drivers and comprehending the genetic basis of fungal drug resistance evolution is pertinent, considering increasing numbers of patients with COVID-19 infections who are sensitive to opportunistic fungal infections. This article emphasises the prevalence and underlying mechanisms of azole resistance in Aspergillus species, with a focus on environmental triggers and resistance development. It also highlights the need for regular surveillance of pesticide use in agriculture, detection of triazole-resistant Aspergillus species in environmental and clinical settings and development of new antifungal drugs.","PeriodicalId":11326,"journal":{"name":"Drug Target Insights","volume":" ","pages":"25-35"},"PeriodicalIF":2.7,"publicationDate":"2022-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c1/e3/dti-16-25.PMC9685629.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40570481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Redefining genomic view of Clostridioides difficile through pangenome analysis and identification of drug targets from its core genome. 通过全基因组分析重新定义艰难梭菌的基因组观，并从其核心基因组中鉴定药物靶点。

IF 2.7

Drug Target Insights Pub Date : 2022-11-11 eCollection Date: 2022-01-01 DOI: 10.33393/dti.2022.2469

Nikita Chordia Golchha, Anand Nighojkar, Sadhana Nighojkar

{"title":"Redefining genomic view of Clostridioides difficile through pangenome analysis and identification of drug targets from its core genome.","authors":"Nikita Chordia Golchha, Anand Nighojkar, Sadhana Nighojkar","doi":"10.33393/dti.2022.2469","DOIUrl":"https://doi.org/10.33393/dti.2022.2469","url":null,"abstract":"ABSTRACT Introduction: Clostridioides difficile infection (CDI) is a leading cause of gastrointestinal infections and in the present day is a major concern for global health care system. The unavailability of specific antibiotics for CDI treatment and its emerging cases worldwide further broaden the challenge to control CDI. Methods: The availability of a large number of genome sequences for C. difficile and many bioinformatics tools for genome analysis provides the opportunity for in silico pangenomic analysis. In the present study, 97 strains of C. difficile were used for pangenomic studies and characterized for their phylogenomic and functional analysis. Results: Pangenome analysis reveals open pangenome of C. difficile and high genetic diversity. Sequence and interactome analysis of 1,481 core genes was done and eight potent drug targets are identified. Three drug targets, namely, aminodeoxychorismate synthase (PabB), D-alanyl-D-alanine carboxypeptidase (DD-CPase) and undecaprenyl diphospho-muramoyl pentapeptide beta-N-acetylglucosaminyl transferase (MurG transferase), have been reported as drug targets for other human pathogens, and five targets, namely, bifunctional diguanylate cyclase/phosphodiesterase (cyclic-diGMP), sporulation transcription factor (Spo0A), histidinol-phosphate transaminase (HisC), 3-deoxy-7-phosphoheptulonate synthase (DAHP synthase) and c-di-GMP phosphodiesterase (PdcA), are novel. Conclusion: The suggested potent targets could act as broad-spectrum drug targets for C. difficile. However, further validation needs to be done before using them for lead compound discovery.","PeriodicalId":11326,"journal":{"name":"Drug Target Insights","volume":" ","pages":"17-24"},"PeriodicalIF":2.7,"publicationDate":"2022-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/74/da/dti-16-17.PMC9669665.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40720644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

The association of ESBL Escherichia coli with mortality in patients with Escherichia coli bacteremia at the emergency department. ESBL大肠杆菌与急诊科大肠杆菌血症患者死亡率的关系

IF 2.7

Drug Target Insights Pub Date : 2022-10-17 eCollection Date: 2022-01-01 DOI: 10.33393/dti.2022.2422

Pariwat Phungoen, Jessada Sarunyaparit, Korakot Apiratwarakul, Lumyai Wonglakorn, Atibordee Meesing, Kittisak Sawanyawisuth

{"title":"The association of ESBL Escherichia coli with mortality in patients with Escherichia coli bacteremia at the emergency department.","authors":"Pariwat Phungoen, Jessada Sarunyaparit, Korakot Apiratwarakul, Lumyai Wonglakorn, Atibordee Meesing, Kittisak Sawanyawisuth","doi":"10.33393/dti.2022.2422","DOIUrl":"https://doi.org/10.33393/dti.2022.2422","url":null,"abstract":"ABSTRACT Background: Escherichia coli is a common bloodstream infection pathogen in the emergency department (ED). Patients with extended-spectrum beta-lactamase (ESBL) E. coli have a higher risk of morbidity. However, there is still debate surrounding ESBL E. coli-associated mortality in community, intensive care unit, and tertiary care settings. In addition, there have been few studies regarding mortality in ESBL E. coli in ED settings, and results have been contradictory. Methods: This was a retrospective cohort study conducted at the Department of Emergency Medicine, Faculty of Medicine, Khon Kaen University in Thailand aimed at evaluating the possible association between ESBL E. coli bacteremia and mortality in the ED. The inclusion criteria were age 18 years or over, clinical presentation suspicious of infection, and positive blood culture for E. coli. Predictors for mortality were analyzed by logistic regression analysis. Results: During the study period, 273 patients presented at the ED with hemoculture positive for E. coli. Of those, 27 (9.89%) died. Five factors remained in the final model, of which plasma glucose levels, serum lactate levels, and ESBL E. coli were significantly associated with 28-day mortality in the ED with adjusted odds ratios of 0.970, 1.258, and 12.885, respectively. Plasma glucose of less than 113 mg/dL yielded a sensitivity of 80.95% and specificity of 64.29%, while serum lactate over 2.4 mmol/L had a sensitivity of 81.48% and specificity of 45.50%. Conclusion: ESBL E. coli, plasma glucose, and serum lactate levels were associated with 28-day mortality in patients with E. coli bacteremia presenting at the ED.","PeriodicalId":11326,"journal":{"name":"Drug Target Insights","volume":" ","pages":"12-16"},"PeriodicalIF":2.7,"publicationDate":"2022-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2b/73/dti-16-12.PMC9589459.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40652791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1